Browsing by Author Iland, Harry

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 18 of 18
Issue DateTitleAuthor(s)Citation
2012All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Bradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Browett, Peter; Catalano, Alberto; Collins, Marnie; Dilulio, J.; et al, various; Firkin, Frank; Grigg, Andrew P.; Hugman, Amanda; Reynolds, John; Supple, Shane; Tiley, Campbell; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineAll-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4), Blood, vol.120, 8, 2012,pp 1570-1580
2007Clinical perspectives in lymphomaIland, Harry; Young, Graham; Central Clinical School: Medicine; Central Clinical School: MedicineClinical perspectives in lymphoma, Internal Medicine Journal, vol.37,(7),2007,pp 478-484
2017Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraIland, Harry; Appelbaum, Frederick; Collins, Marnie; Devlin, Sean; Douer, Dan; et al, Various; Goldman, Debra; Lee, Ju-Whei; Litzow, Mark; Mantha, Simon; Stein, Eytan; Zannino, Diana; Central Clinical School: MedicineDeterminants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era, Blood, vol.129, 13, 2017,pp 1763-1767
2002Diagnosis and molecular monitoring of acute promyelocytic leukemia using DzyNA reverse transcription-PCR to quantify PML/RAR alpha fusion transcriptsIland, Harry; Applegate, Tanya L.; Mokany, Elisa; Todd, Alison V.; Central Clinical School: MedicineDiagnosis and molecular monitoring of acute promyelocytic leukemia using DzyNA reverse transcription-PCR to quantify PML/RAR alpha fusion transcripts, Clinical Chemistry (Washington, DC): international journal of molecular diagnostics and laboratory medicine, vol.48,(8),2002,pp 1338-1343
2002Disseminated granulocytic sarcoma treated with allogeneic peripheral blood stem-cell transplantationIland, Harry; Stevenson, W.S.; Vincent, P.C.; Central Clinical School: MedicineDisseminated granulocytic sarcoma treated with allogeneic peripheral blood stem-cell transplantation, Leukemia & lymphoma, vol.43, 11,pp 2221-2224
2014Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.Iland, Harry; Seymour, John F.; Wei, Andrew; Central Clinical School: MedicineHave all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care., Best Practice & Research: Clinical Haematology, vol.27, 1, 2014,pp 39-52
2013Leukaemias into the 21st century - part 2: the chronic leukaemiasBrown, Catherine; Gibson, John; Iland, Harry; Joshua, Douglas; Larsen, S; Science Faculty Admin; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; MedicineLeukaemias into the 21st century - part 2: the chronic leukaemias, Internal Medicine Journal, vol.43, 5, 2013,pp 484-494
2013Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balanceBryant, Christian; Fromm, Phillip; Hart, Derek; Ho, Phoebe (Joy); Iland, Harry; Joshua, Douglas; Aklilu, Esther; Brown, Ross; Favaloro, James; Gibson, J; Nassif, N; Suen, Hayley; Woodland, N. B.; Yang, S; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineLong-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance, Blood Cancer Journal, vol.3, N/A, 2013,pp 1-7
2005Molecular biology of lymphoma in the microarray era.Iland, Harry; Catalano, Alberto; Central Clinical School: MedicineMolecular biology of lymphoma in the microarray era., Pathology 2005, vol.37,(6),2005,pp 508-522
2002Molecular monitoring of acute promyelocytic leukemia by DzyNA reverse transcription-PCRIland, Harry; Applegate, Tanya L.; Mokany, Elisa; Todd, Alison V.; Central Clinical School: MedicineMolecular monitoring of acute promyelocytic leukemia by DzyNA reverse transcription-PCR, Clinical Chemistry (Washington, DC): international journal of molecular diagnostics and laboratory medicine, vol.48,(10),2002,pp 1858-1860
2014Optimal approach for high-risk acute promyelocytic leukemiaIland, Harry; Seymour, John F.; Wei, Andrew; Central Clinical School: MedicineOptimal approach for high-risk acute promyelocytic leukemia, Current Opinion In Hematology, vol.21, 4, 2014,pp 102-113
2015A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemiaBradstock, Kenneth; Iland, Harry; Kerridge, Ian; McLachlan, Andrew; Boyd, Andrew; Busfield, Samantha; Durrant, Simon; et al, Various; He, Simon Z; Hertzberg, Mark; Kennedy, G; Lewis, Ian D.; Marlton, Paula; Ritchie, David S; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Medicine; School of Public Health: Ctr for Values Ethics & Law in Med; PharmacyA Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia, Leukemia & Lymphoma, vol.56, 5, 2015,pp 1406-1415
2007The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemiaIland, Harry; Campbell, Lynda J.; Catalano, Alberto; Dawson, Mark A.; Opat, Stephen; Schwarer, Anthony; Somana, Karthiga; Central Clinical School: MedicineThe PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia, Blood, vol.110,(12),2007,pp 4073-4076
2012Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Allen, John; Al-Shabeeb, Ammira; Ho, Phoebe (Joy); Iland, Harry; Joshua, Douglas; Lau, Edwin; Ling, Silvia; Nikolic, Angela; Catalano, Alberto; Fleming, Shaun; Harrison, Simon James; Horvath, N; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Melanoma FoundationResponse of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1, Haematologica: the hematology journal, vol.97, 1, 2012,pp 64-72
2012Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaBradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Brighton, Tim; Browett, Peter; Cannell, P; Catalano, J; Deveridge, Sandra; et al, various; Grigg, A; Horvath, Noemi; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineResults of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia, Haematologica: the hematology journal, vol.97, 2, 2012,pp 227-234
2017Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectivesIland, Harry; Brown, Christina; McCulloch, Derek; Central Clinical School: MedicineRetinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives, OncoTargets and Therapy, vol.10, N/A, 2017,pp 1585-1601
2013Role of arsenic trioxide in acute promyelocytic leukemiaIland, Harry; Seymour, John F.; Central Clinical School: MedicineRole of arsenic trioxide in acute promyelocytic leukemia, Current Treatment Options in Oncology, vol.14, 2, 2013,pp 170-184
2015Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialBradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Browett, Peter; Campbell, Lynda J.; Catalano, Alberto; Collins, Marnie; Di Iulio, Juliana L.; et al, Various; Firkin, Frank; Grigg, Andrew P.; Hugman, Amanda; Reynolds, John; Supple, Shane; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineUse of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial, The Lancet Haematology, vol.2, 9, 2015,pp e357-e366